Travere Therapeutics, INC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 1,572,539 shares, representing 1.67% of the outstanding common stock of Travere Therapeutics, Inc.

Bank of America Corporation has reported a beneficial ownership of 5.8% in Travere Therapeutics, Inc., holding over 5.4 million shares as of June 30, 2026.

State Street Corporation has disclosed beneficial ownership of 4.6% of Travere Therapeutics Inc.'s common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.27% in Travere Therapeutics, Inc., holding 4,897,417 shares of common stock.

Vanguard Capital Management has reported beneficial ownership of 5.09% of Travere Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Travere Therapeutics Inc. following an internal corporate realignment.

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Travere Therapeutics Inc.

State Street Corporation has reported a 5.3% beneficial ownership stake in Travere Therapeutics Inc. common stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported an 11.7% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 7.52% in Travere Therapeutics, Inc., holding 6,724,000 shares of common stock.

Janus Henderson Group plc has reported an 11.9% beneficial ownership stake in Travere Therapeutics, Inc. common stock.

Perceptive Advisors LLC and affiliates have reported a 5.5% beneficial ownership stake in Travere Therapeutics, Inc., signaling significant institutional interest.

Armistice Capital and Steven Boyd have increased their beneficial ownership in Travere Therapeutics, Inc. to 9.96% of common stock.

Janus Henderson Group plc has reported an increased beneficial ownership of 12.8% in Travere Therapeutics, Inc., holding over 11.3 million shares.

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Travere Therapeutics Inc. as of June 30, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 9.99% in Travere Therapeutics, Inc.'s common stock as of March 31, 2025.

Rock Springs Capital Management LP and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 3.3% in Travere Therapeutics, Inc. common stock.

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 5.41% in Travere Therapeutics Inc. common shares as of March 31, 2025.

Janus Henderson Group PLC has filed a Schedule 13G, reporting a beneficial ownership of 8.5% of Travere Therapeutics, Inc.'s common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 5.65% beneficial ownership stake in Travere Therapeutics Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 11 to its Schedule 13G, reporting a 7.5% beneficial ownership stake in Travere Therapeutics, Inc. as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.62% in Travere Therapeutics, Inc., totaling 7,358,000 shares of common stock.

Woodline Partners LP, an investment adviser, has disclosed a 2.4% passive beneficial ownership stake in Travere Therapeutics, Inc. as of December 31, 2024.

Rock Springs Capital Management LP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 5.72% of Travere Therapeutics, Inc.'s common stock as of December 31, 2024.

Macquarie Group Limited and its subsidiaries have filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.4% beneficial ownership stake in Travere Therapeutics, Inc. as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.75% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2024.